Press Releases

BRISBANE, Calif. , July 13, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that the landmark

PAMA to provide pricing certainty for high value diagnostic testing

CareDx further bolsters clinical evidence

Late-breaking DART data presented at ASN meeting in Chicago

Defines Cell-free DNA Levels in Stable Kidney Transplant Patients

Cell-free-DNA test identifies active rejection in kidney transplant patients

Alongside AlloSure Heart Validation, CareDx advances SHORE enrollment    BRISBANE, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

New data highlights the value of AlloSure to detect rejection in one of the most complex transplanted organs BRISBANE, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

CareDx at the Forefront of Personalized Medicine in Transplantation CareDx to hold Conference Call on June 13, 2016 at 4pm ET BRISBANE, Calif. , June 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization

CareDx Files Second Lawsuit Against Natera BRISBANE, Calif. , April 10, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc.